Obesity
Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
Published in Obesity and Diabetes Week, January 21st, 2008
Nastech Pharmaceutical Company Inc. (NASDAQ:NSTK) announced the completion of enrollment for its Phase 2 clinical trial of PYY3-36 Nasal Spray to treat obesity. The Company enrolled 551 obese patients at multiple clinical sites in the United States for a six-month, randomized, placebo-controlled dose ranging study. The study is designed to evaluate three different doses of PYY3-36 Nasal Spray compared to placebo and sibutramine (Meridia(R)), a commercially available oral weight loss drug, with the primary endpoint being weight loss.
"We are pleased with the rapid enrollment of 551 patients into the Phase 2 study to evaluate PYY3-36 nasal spray as a novel treatment for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Obesity
Eating out can have both positive and negative impact on obesity - Obesity and Diabetes
Diabetes medication and lifestyle changes can help treat weight gain induced by antipsychotic drugs - Alcoholism
Data on alcoholism detailed by T. Nishide and co-authors - Cardiovascular Disease
Research from University of Otago provides new data on cardiovascular disease - Cardiovascular Disease
Research on cardiovascular disease published by M.A.C. Smith et al - Cardiovascular Risk
Findings from University of Edinburgh broaden understanding of cardiovascular risk - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
